We report the first visible cytogenetic deletion involving the NF1 gene in a patient with sporadic neurofibromatosis, dysmorphic features, and marked developmental delay. The combined evidence of molecular and cytogenetic techniques based on dosage reduction, hemizygosity for microsatellite markers, high resolution G banding, and FISH analysis, predicts this deletion to be approximately 7 Mb in size. Our findings highlight the importance of conducting a detailed cytogenetic and FISH analysis in patients with NFl who have additional dysmorphic features or particularly severe learning difficulties.
estimated at 1 x 1 04/gamete/generation, is approximately 10-fold higher than that reported for any other single human locus. New mutations appear to be predominantly of paternal origin"" and account for approximately 50% of the cases.
Approximately 130 separate mutations have been reported to the NFI Genetic Analysis Consortium, of which over 90 have been published. ' 2 Despite the high mutation rate observed at the NFl locus, only a few mutations have been fully characterised.'3 The rate of mutation detection in the NF1 gene has been low over the last five years. The alterations so far reported include translocations, molecular deletions, insertions, substitutions, and nonsense mutations. This is the first report to describe a cytogenetic deletion involving the NF1 gene in a patient with neurofibromatosis associated with dysmorphism and developmental delay.
Neurofibromatosis type 1 is an autosomal dominent disorder, characterised by marked variation in expression, affecting approximately 1 in 3000 people.' The main clinical features of the disease are cafe au lait spots, cutaneous neurofibromas, and hamartomas of the iris (Lisch nodules). Additional complications associated with the disease include central nervous system tumours, scoliosis, plexiform neurofibromas, learning difficulties, and epilepsy. 2 The gene for NF 1 has been mapped to 17qll. 23 The gap between the YAC clones is approximately 60 kb in size. These probes were premixed with blocking DNA in Hybrisol VII (50%, formamide, 2 x SSC) according to a standard protocol (Oncor). Slides were denatured in 70% formamide/2 x SSC, pH 7 at 70°C for two minutes and hybridised overnight at 370C in a humidified chamber with the probe mixture. The post-hybridisation washes were in 50% formamide/2 x SSC, pH 7 at 43°C for 15 minutes, followed by 2 x SSC, pH 7 at 37°C for eight minutes. Detection was achieved by successive applications of monoclonal mouse antidigoxygenin, fluorescein isothyiocyanate (FITC)-conjugated rabbit antimouse antibody, and FITC-conjugated goat antirabbit antibody (Sigma). The preparations were counterstained with propidium iodide and 4', 6-diamidino-2-phenylindole (DAPI). The slides were examined with a Zeiss Axioplan epifluoresence microscope equipped for viewing FITC, DAPI, and propidium iodide and photographed using Kodachrome 400 film.
Results
Of the 15 polymorphic markers used, four were not informative. In the remaining 11, 10 markers identified a single allele band in the patient. Analysis of microsatellites present in introns 27 and 38 indicated that the patient had failed to inherit a paternal allele (figs 2 and 3). A reduction in the level of hybridisation was also observed when the DNA from the patient was screened with cDNAs AE25, P5, B3A, and the extragenic markers P8.2, EW206, and EW207, indicating hemizygosity at these loci (data not shown).
A cytogenetic deletion, del(17) (qll.22q21. 1), in a patient with sporadic neurofibromatosis type 1 (NF1) Analysis with the 17p polymorphic probe EW301 localised to 17p showed the patient was heterozygous at this locus. The combined evidence of (1) dosage reduction within or near to the NF1 gene, (2) hemizygosity for microsatellite marker within introns 27 and 38, and (3) heterozygosity at the EW301 locus which maps to 17p supports the view that this patient has developed the disease (NF1) as the result of a de novo NF1 gene deletion of paternal origin rather than uniparental disomy.
Pulsed field gel electrophoresis with NF cDNA probes did not show any evidence of altered band pattern. Clearly, DNA markers closely flanking the end point of this deletion are required to define the extent ofthis deletion.
RT-PCR based analysis of RNA in our patient with previously published primer set III22 spanning nucleotides 2315 to 2815 showed the transcription of an expected 500 bp normal allele. The remaining allele has not undergone any rearrangements; Western blot analysis (a Downward, personal communication) also showed the presence of a normal size neurofibromin.
Cytogenetic investigation showed that the G banding pattern was consistent with a small interstitial deletion within the proximal part of the long arm of chromosome 17. High resolution studies indicated that the breakpoints were in sub-bands qll.22 and q21.1 (fig 4) . This view was supported by the FISH results. Studies on both a lymphocyte culture and a lymphoblastoid cell line showed that the YACs A43A9 and Al13D7 were deleted in the abnormal chromosome 17 ( fig 5, top) . The RARA gene probe maps to the chromosome 17 breakpoint in the translocation t(15;17) (q22;q12 or 21.1) found in acute promyelocytic leukaemia. The signal from this probe was present in the deleted chromosome 17, but was displaced proximally towards the centromere, whereas both SMCR probe signals were located in the normal position on the two chromosome 17 homologues (fig 5, bottom) . Direct measurement of pairs of standardised, enlarged, and straightened chromosome 17 homologues from 13 G banded prometaphase cells indicated that the deletion chromosome was about 8% shorter than the normal chromosome 17. This was estimated to be equivalent to a deletion of 7.4 megabase pairs (Mb) which, based on the assumption that the total number of genes in the haploid genome is 50 to 100 000, may have resulted in the loss of between 60 has marked problems with both his speech and his mobility. His phenotype is not consistent with any recognisable syndrome and no definite diagnosis had been suggested before his development of multiple cafe au lait spots and axillary and inguinal freckling.
The patient in this study appears to be another sporadic NF1 case with a contiguous gene deletion syndrome,3' although genes tightly flanking the NFl locus have yet to be identified. Detailed molecular analysis of the size of the deletions and location of their breakpoints in all the cases involving the deletion of the entire NF1 gene will facilitate our understanding of the role of different flanking genes in the expression of the observed developmental delay and dysmorphic phenotype.
The lack of inheritance of the paternal allele indicates that the deletion must have occurred during spermatogenesis in the father. Studies with closely linked polymorphic markers have shown that approximately 95% of all new NFl mutations are of paternal origin.'0"' However, in a recent study using intragenic markers, deletions observed in four of the 15 families studied, were of maternal origin.32 For Duchenne muscular dystrophy (DMD), the vast majority of deletions arise in oogenesis, while most point mutations stem from spermatogenesis.33 A similar finding has been reported for factor 934 and ZFX and ZFY genes.35
It will be important to determine whether such a bias in origin of new mutations occurs in the NF1 gene.
Benign neurofibromas in NFI have not shown any loss of heterozygosity or large scale rearrangements, perhaps because of polyclonality. The molecular study of neurofibromas in the patient with the entire deletion of the NFl gene will allow easier detection and characterisation of the second hit, since one allele is already missing.
It is interesting to speculate whether visible cytogenetic deletions are actually rare in the NF1 patients or if the analysis has simply not been sufficiently detailed. In an initial analysis ofa lymphocyte culture (carried out elsewhere), and on examination of the cultured skin cells from this patient, the cytogenetic deletion was not discernible but was 
